Last reviewed · How we verify

NCT02690155: RIVA-F

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Completed Last updated 5 April 2017
What this trial tests

trial testing Rivaroxaban (Xarelto, BAY59-7939) in Atrial Fibrillation in 38,831 participants. Completed in 1 March 2016.

Timeline
12 February 2016
Primary endpoint
1 March 2016
1 March 2016

Quick facts

Lead sponsorBayer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment38,831
Start date12 February 2016
Primary completion1 March 2016
Estimated completion1 March 2016
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Rivaroxaban (Xarelto, BAY59-7939)

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Bayer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02690155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing